Tonix Pharmaceuticals Holding Corp.’s TNXP share price has dipped by 10.75%, which has investors questioning if this is right ...

Tonix Pharmaceuticals (TNXP) announced a collaborative research agreement under which Tonix and Makana will study Tonix’s anti-CD40L monoclonal ...

Tonix Pharmaceuticals (TNXP) presented data in a poster presentation at the AAPM 2025 Annual Meeting, held April 3-6, 2025, in Austin, Texas.

Stock analysts at Zacks Small Cap issued their Q1 2025 EPS estimates for shares of Tonix Pharmaceuticals in a report released on Thursday, April 3rd. Zacks Small Cap analyst D. Bautz anticipates that ...

Tonix Pharmaceuticals (NASDAQ:TNXP – Get Free Report) will likely be announcing its earnings results before the market opens ...

Shares of Tonix Pharmaceuticals are pulling back 12.7% during Thursday's session. The stock is pulling back following a regulatory update on its experimental fibromyalgia treatment, TNX-102 SL.

Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal ...

TNXP READ THE FULL TNXP RESEARCH REPORT Business Update No Advisory Committee Meeting for TNX-102 SL NDA On March 24, 2025, ...

TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal delivery and durable activity in treating fibromyalgia TNX-102 SL demonstrated statistically significant ...

Detailed price information for Tonix Pharm Holdings (TNXP-Q) from The Globe and Mail including charting and trades.

CHATHAM, NEW JERSEY / ACCESS Newswire / March 31, 2025 / This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding ...